Clinical Observation on Baogankang （葆肝康） Formula Combined with Entecavir in Treating 32 Cases with Chronic Hepatitis B of Stagnation of Liver Qi and Spleen Deficiency Type

ZHANG Yufeng; ZHONG Dan; DANG Zhongqin; GUO Wei

doi:10.13288/j.11-2166/r.2016.19.014

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on Baogankang （葆肝康） Formula Combined with Entecavir in Treating 32 Cases with Chronic Hepatitis B of Stagnation of Liver Qi and Spleen Deficiency Type

更新时间：2021-11-17

- Clinical Observation on Baogankang （葆肝康） Formula Combined with Entecavir in Treating 32 Cases with Chronic Hepatitis B of Stagnation of Liver Qi and Spleen Deficiency Type
- Journal of Traditional Chinese Medicine Vol. 57, Issue 19, Pages: 1674-1677(2016)
- 作者机构：
  
  1. 河南中医药大学第二临床医学院
  2. 井冈山大学附属医院
  3. 江阴天江药业有限公司
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2016.19.014
  CLC： R512.62
- Published：2016
- 稿件说明：
移动端阅览
[1]张玉峰,钟丹,党中勤,郭巍.葆肝康配方联合恩替卡韦治疗慢性乙型肝炎肝郁脾虚型32例临床观察[J].中医杂志,2016,57(19):1674-1677.

ZHANG Yufeng, ZHONG Dan, DANG Zhongqin, et al. Clinical Observation on Baogankang （葆肝康） Formula Combined with Entecavir in Treating 32 Cases with Chronic Hepatitis B of Stagnation of Liver Qi and Spleen Deficiency Type[J]. Journal of Traditional Chinese Medicine2016, 57(19): 1674-1677.
[1]张玉峰,钟丹,党中勤,郭巍.葆肝康配方联合恩替卡韦治疗慢性乙型肝炎肝郁脾虚型32例临床观察[J].中医杂志,2016,57(19):1674-1677. DOI： 10.13288/j.11-2166/r.2016.19.014.

ZHANG Yufeng, ZHONG Dan, DANG Zhongqin, et al. Clinical Observation on Baogankang （葆肝康） Formula Combined with Entecavir in Treating 32 Cases with Chronic Hepatitis B of Stagnation of Liver Qi and Spleen Deficiency Type[J]. Journal of Traditional Chinese Medicine2016, 57(19): 1674-1677. DOI： 10.13288/j.11-2166/r.2016.19.014.

摘要

目的观察葆肝康配方联合恩替卡韦治疗慢性乙型肝炎的临床疗效。方法将66例慢性乙型肝炎（肝郁脾虚型）患者随机分为治疗组及对照组各33例

对照组患者口服恩替卡韦分散片0.5 mg

每日1次;复方甘草酸苷注射液100 ml

静脉滴注

每日1次;治疗组患者在对照组治疗的基础上

加用葆肝康配方每日1剂

早晚饭后1 h分两次冲服。两组疗程均为2个月。治疗前后分别观察两组肝功能[包括丙氨酸氨基转移酶（ALT）、门冬氨酸氨基转移酶（AST）、总胆红素（TBIL）]、血清纤维化指标[包括Ⅲ型前胶原（PCⅢ）、Ⅳ型胶原（Ⅳ-C）、层粘连蛋白（LN）、透明质酸酶（HA）]、凝血酶原时间（PT）、症状和体征积分

并评价临床疗效。结果治疗组总有效率为93.75%;对照组总有效率为75.00%

治疗组优于对照组（P<0.05）。两组治疗后ALT、AST、TBIL均较治疗前下降（P<0.05）

且治疗组较对照组降低明显（P<0.05）。治疗组治疗后HA、Ⅳ-C、PCⅢ、LN均较治疗前明显降低（P<0.01）

且治疗组较对照组降低明显（P<0.01）。治疗后两组PT较治疗前明显降低（P<0.05）

但组间比较

差异无统计学意义（P>0.05）;治疗组治疗后症状积分较治疗前明显降低（P<0.05）

且明显低于对照组（P<0.05）。结论葆肝康配方联合恩替卡韦能够显著改善慢性乙型肝炎患者肝功能及凝血功能

缓解肝纤维化

改善症状。

Abstract

Objective To observe clinical effects of Baogankang（葆肝康） formula combined with entecavir treating chronic hepatitis B. Methods Sixty-six patients with chronic hepatitis B of stagnation of liver Qi and spleen deficiency type were randomly divided into treatment group and control group with 33 in each. The control group took entecavir dispersible tablets

0. 5 mg

once a day

and made intravenous drip with Compound Glycyrrhizin injection

100 ml

once a day. Based on the treatment in the control group

the treatment group also took Baogankang formula 1 dose a day

one half at 1 h after meals in the morning and the other half in the evening. The treatment in both groups last for 2 months. The researchers respectively observed Liver function including alanine aminotransferase（ ALT）

aspartate aminotransferase（ AST） and total bilirubin（ TBIL）

serum fibrosis index including procollagen Ⅲ（ PCⅢ）

Ⅳ-collagen（ Ⅳ-C）

laminin（ LN） and hyaluronidase（ HA）

prothrombin time（ PT）

scores of signs and symptoms and evaluated clinical effects before and after treatment in the two groups. Results The total effective rate in the treatment group was 93. 75 %

but in the control group was 75. 00 %. The treatment group is better than the control group（ P < 0. 05）. Compared with those before treatment

ALT

AST and TBIL decreased after treatment in both groups（ P < 0. 05）

and those in the treatment group reduced more significantly than that in the control group（ P < 0. 05）. Compared with those before treatment

Ⅳ-C

PC Ⅲ and LN decreased obviously after treatment in the treatment group（ P < 0. 01）

and those in the treatment group reduced more significantly than that in the control group（ P < 0. 01）. Compared with that before treatment

PT decreased obviously after treatment in both groups（ P < 0. 05）

but there was no statistically difference in the comparison between groups（ P > 0. 05）;Compared with that before treatment

scores of symptoms decreased obviously after treatment in the treatment group（P < 0. 05）

and were significantly lower than those in the control group（ P < 0. 05）. Conclusion Baogankang formula combined with entecavir can significantly improve liver function and coagulation function

and alleviate hepatic fibrosis and improve symptoms of patients with chronic hepatitis B.

关键词

Keywords

references

查看原文

Views

166

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The Effects of Huqi Zhengxiao Formula （槲芪癥消方） on the Survival Rate and Quality of Life of Patients of Stage Ⅲ Hepatitis B-Associated Primary Liver Cancer with Syndrome of Healthy Qi Deficiency， Toxic Stasis Accumulation After Transcatheter Arterial Chemoembolisation Treatment

Effect of Longchai Formula （龙柴方） Drug-containing Serum Combined with Entecavir on P-glycoprotein and PI3K/AKT Signaling Pathway in HepG2.2.15 Hepatocellular Carcinoma Cells

Literature Research of Medication Rule of Chinese Medicine Treatment of Chronic Hepatitis B by Syndrome Differentiation

Synergistic Effect of Multi-Ways Chinese Medication on Routine Therapy for Hepatitis B Virus Related Acute-On-Chronic Liver Failure

TCM Syndrome Distribution of 2 958 Hepatitis B Virus Infection Subjects

Related Author

ZHANG Chun

WANG Xiaojun

LI Jingying

XU Wenjun

YAN Zhanpeng

ZHENG Xue

LI Kun

XU Tingting

Related Institution

Peking University Third Hospital

Beijing Youan Hospital， Capital Medical University

Jiangsu Province Hospital on Integration of Chinese and Western Medicine

Jinagsu Province Academy of Traditional Chinese Medicine

The Third School of Clinical Medicine， Nanjing University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰